Chu, Yanshuo
Dai, Enyu
Li, Yating
Han, Guangchun http://orcid.org/0000-0001-9277-2507
Pei, Guangsheng
Ingram, Davis R.
Thakkar, Krupa
Qin, Jiang-Jiang
Dang, Minghao
Le, Xiuning http://orcid.org/0000-0002-8554-1185
Hu, Can
Deng, Qing
Sinjab, Ansam http://orcid.org/0000-0001-5777-227X
Gupta, Pravesh http://orcid.org/0000-0002-1643-8950
Wang, Ruiping
Hao, Dapeng http://orcid.org/0000-0002-9043-371X
Peng, Fuduan
Yan, Xinmiao
Liu, Yunhe http://orcid.org/0000-0002-2120-952X
Song, Shumei http://orcid.org/0000-0002-8128-6287
Zhang, Shaojun http://orcid.org/0000-0001-5760-5797
Heymach, John V. http://orcid.org/0000-0001-9068-8942
Reuben, Alexandre http://orcid.org/0000-0003-4510-0382
Elamin, Yasir Y. http://orcid.org/0000-0002-5312-909X
Pizzi, Melissa P.
Lu, Yang http://orcid.org/0000-0001-9571-4679
Lazcano, Rossana
Hu, Jian
Li, Mingyao http://orcid.org/0000-0001-8180-0621
Curran, Michael http://orcid.org/0000-0003-4996-7207
Futreal, Andrew http://orcid.org/0000-0001-8663-2671
Maitra, Anirban http://orcid.org/0000-0001-7923-9978
Jazaeri, Amir A. http://orcid.org/0000-0003-4335-4151
Ajani, Jaffer A. http://orcid.org/0000-0001-9946-0629
Swanton, Charles http://orcid.org/0000-0002-4299-3018
Cheng, Xiang-Dong
Abbas, Hussein A. http://orcid.org/0000-0003-2946-3562
Gillison, Maura
Bhat, Krishna http://orcid.org/0000-0002-2020-8509
Lazar, Alexander J. http://orcid.org/0000-0002-6395-4499
Green, Michael http://orcid.org/0000-0001-6309-9472
Litchfield, Kevin
Kadara, Humam http://orcid.org/0000-0003-2976-9115
Yee, Cassian http://orcid.org/0000-0002-4429-7307
Wang, Linghua http://orcid.org/0000-0001-9380-0266
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA264583)
Cancer Prevention and Research Institute of Texas (RP200385, RP220101)
Article History
Received: 14 December 2021
Accepted: 26 April 2023
First Online: 29 May 2023
Competing interests
: A.A.J. has served as a consultant for Guidepoint, Gerson Lehrman Group, Nuprobe, AvengeBio, Agenus, AstraZeneca, Iovance, Bristol-Myers Squibb, Eisai, GSK/Tesaro, Macrogenics, Instill Bio, Immune-Onc Therapeutics, Obsidian, Alkermes and Roche/Genentech and he receives research support to his institution from AstraZeneca, Bristol-Myers Squibb, Merck, Eli Lilly, Pfizer, Aravive and Iovance. He is a shareholder in AvengeBio. A.M. receives royalties from Cosmos Wisdom Biotechnology and Thrive Earlier Detection, an Exact Sciences Company. A.M. is also a consultant for Freenome and Tezcat Biotechnology. A.R. has received honoraria and serves on the scientific advisory board of Adaptive Biotechnologies. H.K. reports funding from Johnson and Johnson. M.R.G. receives research funding from Allogene, Kite/Gilead, Sanofi and Abbvie, has received honoraria from Monte Rosa Therapeutics, Daiichi Sankyo and Tessa Therapeutics and has stock ownership interest in KDAc Therapeutics. X.L. reports consulting or advisory role for EMD Serono (Merck KGaA), AstraZeneca, Spectrum Pharmaceutics, Novartis, Eli Lilly, Boehringer Ingelheim and Bristol-Myers Squibb, Dachii, Hengrui Therapeutics and she receives research funding from Lilly (Inst), Boehringer Ingelheim (Inst) and Regeneron (Inst). Y.Y.E reports research funding from Spectrum Pharmaceuticals, AstraZeneca, Takeda, Xcovery, Lilly, Elevation Oncology, Turning Point Therapeutics and he serves as a consultant for Lilly, AstraZeneca, Turning Point Therapeutics. J.V.H. reports consulting or advisory role for AstraZeneca, Bristol-Myers Squibb, Spectrum Pharmaceuticals, Guardant Health, Hengrui Pharmaceutical, GlaxoSmithKline, EMD Serono, Lilly, Takeda, Sanofi/Aventis, Genentech/Roche, Boehringer Ingelheim, Catalyst Biotech, Foundation Medicine, Novartis, Mirati Therapeutics, BrightPath Biotheraputics, Janssen, Nexus Health Systems, Pneuma Respiratory, Kairos Ventures, Roche and Leads Biolabs and he receives research funding from AstraZeneca (Inst), Spectrum Pharmaceuticals and GlaxoSmithKline. J.V.H. has a licensing agreement with Spectrum regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations and has stock ownership interest in Cardinal Spine and Bio-Tree. K.L. has a patent on indel burden and CPI response pending and he received honoraria from Roche Tissue Diagnostics and research funding from Cancer Research UK TDL/Ono/LifeArcAlliance and he reports a consulting role with Monopteros Therapeutics. H.K.K. reports funding from Johnson and Johnson. C.S. acknowledges grants from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Roche-Ventana, Invitae, Ono Pharmaceutical and Personalis. He is Chief Investigator for the AZ MeRmaiD 1 and 2 clinical trials and is the Steering Committee Chair. He is also Co-Chief Investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL’s Scientific Advisory Board (SAB). He receives consultant fees from Achilles Therapeutics (also an SAB member), Bicycle Therapeutics (also an SAB member), Genentech, Medicxi, China Innovation Center of Roche formerly Roche Innovation Center, Shanghai, Metabomed and the Sarah Cannon Research Institute. C.S. has received honoraria from Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Illumina, MSD, Novartis, Pfizer and Roche-Ventana. C.S. has previously held stock options in Apogen Biotechnologies and GRAIL and currently has stock options in Epic Bioscience, Bicycle Therapeutics and has stock options and is a co-founder of Achilles Therapeutics. C.S. declares a patent application (PCT/US2017/028013) for methods for lung cancer; targeting neoantigens (PCT/EP2016/059401); identifying patient response to ICB (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004); predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912); and methods for lung cancer detection (US20190106751A1). C.S. is an inventor on a European patent application (PCT/GB2017/053289) relating to assay technology to detect tumor recurrence. This patent has been licensed to a commercial entity and under their terms of employment, C.S. is due a revenue share of any revenue generated from such license(s). The remaining authors declare no competing interests.